Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

Author archives

You are currently viewing all posts written by ltimmerman.

July 12, 2006 at 3:51 PM

ZymoGenetics tests IL-21 as combo with Rituxan

ZymoGenetics said today it has started a clinical trial of Interleukin-21 along with Rituxan, as a combination therapy against non-Hodgkin’s lymphoma. Combination cancer drugs are somewhat in vogue as a way companies can show the FDA their treatments offer an edge in efficacy. If it works, the combination is bound to give health insurers headaches —…


Comments | More in Biotechnology